Premium
An Antioxidant Enzyme Therapeutic for COVID‐19
Author(s) -
Qin Meng,
Cao Zheng,
Wen Jing,
Yu Qingsong,
Liu Chaoyong,
Wang Fang,
Zhang Jianjun,
Yang Fengmei,
Li Yanyan,
Fishbein Gregory,
Yan Sen,
Xu Bin,
Hou Yi,
Ning Zhenbo,
Nie Kaili,
Jiang Ni,
Liu Zhen,
Wu Jun,
Yu Yanting,
Li Heng,
Zheng Huiwen,
Li Jing,
Jin Weihua,
Pang Shen,
Wang Shuai,
Chen Jianfeng,
Gan Zhihua,
He Zhanlong,
Lu Yunfeng
Publication year - 2020
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.202004901
Subject(s) - catalase , reactive oxygen species , hydrogen peroxide , antioxidant , covid-19 , enzyme , pandemic , virology , pharmacology , biology , biochemistry , medicine , disease , pathology , infectious disease (medical specialty)
The COVID‐19 pandemic has taken a significant toll on people worldwide, and there are currently no specific antivirus drugs or vaccines. Herein it is a therapeutic based on catalase, an antioxidant enzyme that can effectively breakdown hydrogen peroxide and minimize the downstream reactive oxygen species, which are excessively produced resulting from the infection and inflammatory process, is reported. Catalase assists to regulate production of cytokines, protect oxidative injury, and repress replication of SARS‐CoV‐2, as demonstrated in human leukocytes and alveolar epithelial cells, and rhesus macaques, without noticeable toxicity. Such a therapeutic can be readily manufactured at low cost as a potential treatment for COVID‐19.